Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong growth in MRD tests, positive developments in women's health and oncology segments, and promising progress in international markets like Japan. Although there are concerns about gross margins and SG&A expenses, the company's cautious guidance allows room for upside. The Q&A session reveals optimism in new product launches and partnerships, with potential revenue growth from MolDX submissions. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Key Financial Performance
Revenue $697 million in Q1, a 39% growth year-over-year. The growth is attributed to rapid expansion in women's health and oncology, with a record number of units delivered in a single quarter.
Women's Health Volume Approaching a run rate of nearly 200,000 Fetal Focus orders. Growth driven by the successful launch of the Fetal Focus product and strong clinical data from the EXPAND trial.
Oncology Volume Processed 249,000 clinical oncology units in Q1, a 55% growth year-over-year. Growth attributed to new data readouts, publications, and integration with OncoEMR.
Gross Margins Just under 65% in Q1, exceeding the full-year guidance midpoint of 64%. Margins were impacted by a 2 percentage point reduction due to increased samples in process, which is expected to normalize.
Signatera ASP (Average Selling Price) Approximately $1,250, an increase of $25 from Q4. Growth driven by better alignment with Medicare Advantage plans and improved bundled pricing from CMS.
R&D Investment Increased by $50 million to accelerate oncology clinical trials, including the FIND ECD study, which is ahead of schedule.
MRD (Molecular Residual Disease) Volume Nearly 250,000 tests in Q1, with a run rate of over 1 million annually. Growth driven by new clinical data and expanded commercial footprint.
Stock-Based Compensation Impact on COGS A larger-than-usual charge due to the Foresight acquisition in Q4, impacting gross margins.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Fetal Focus product launch: The Fetal Focus product, a next-generation single-gene NIPT, was successfully launched and is exceeding expectations. It is powered by LinkedSNP technology and addresses gaps in prenatal care. The product is approaching an annualized run rate of 200,000 test orders.
Signatera MRD testing: Signatera MRD testing has shown significant growth, reaching nearly 250,000 tests in Q1, with a run rate of over 1 million tests annually. It is being used across multiple cancer types and has demonstrated clinical utility in avoiding surgeries and guiding treatment decisions.
Japan market expansion: Preparations for the commercial launch of Signatera in Japan are underway, with PMDA approval expected in Q2 2026. Japan represents a significant growth opportunity, particularly in colorectal cancer, with potential to double Signatera's annual CRC volume TAM.
Revenue growth: Q1 revenue reached $697 million, a 39% year-over-year growth. The company raised its full-year revenue guidance by $120 million.
Gross margin improvement: Gross margins exceeded expectations, coming in at just under 65% for Q1. Full-year gross margin guidance was raised to 65% at the midpoint.
ASP improvements: Signatera ASPs increased to approximately $1,250, with further improvements expected throughout the year.
R&D investment: R&D spending was increased by $50 million to accelerate oncology clinical trials, including the FIND ECD study, which is ahead of schedule and expected to complete enrollment by Q3 2026.
Early cancer detection: The FIND CRC study for colorectal cancer screening is progressing ahead of schedule, with enrollment expected to complete by Q3 2026. This study supports the development of a broader early detection platform.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Gross Margins: The rapid increase in volumes in Q1 harmed margins by roughly 2 percentage points due to more samples in process in the lab at the close of the quarter than normal. This impacted the received versus reported ratio, which could affect financial performance temporarily.
R&D Expenditures: Enrollment in oncology clinical trials is ahead of schedule, leading to an increase in R&D expectations by $50 million. This could strain financial resources and impact profitability in the short term.
Reimbursement and ASPs: While Signatera ASPs have increased, delays in cash collections due to changes in bundled pricing caused a temporary step-up in DSOs. This could impact cash flow management.
Operational Efficiency: The company is deploying AI capabilities to drive efficiency, but there is no guarantee these initiatives will yield the expected cost savings or operational improvements.
Regulatory and Market Risks: The company is heavily reliant on Medicare and private payer coverage decisions for ASP growth. Delays or unfavorable decisions could impact revenue projections.
Product Launch Risks: The launch of new products like Fetal Focus and Signatera in Japan involves significant investment and operational complexity, which could pose risks if adoption or market conditions do not meet expectations.
Economic and Competitive Pressures: The company faces competitive pressures in the oncology and diagnostics markets, which could impact market share and pricing power.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has increased its full-year revenue guidance by more than $120 million, reflecting strong performance and growth expectations.
Gross Margin Guidance: Gross margin guidance has been raised to 65% at the midpoint, with potential upside as the year progresses.
Signatera ASP Target: The company aims to achieve a long-term ASP target of $2,000 per test for Signatera, which could generate an additional $750 million in annual revenue and gross profit at current volumes.
Oncology Clinical Trials: Enrollment in oncology clinical trials, including the FIND ECD study, is ahead of schedule, with full enrollment expected by Q3 2026. This supports a 2027 product launch.
Japan Market Launch: The company plans to launch Signatera in Japan in Q2 2026, with PMDA approval on track. This launch could significantly expand the global MRD market and accelerate commercial volumes.
Early Cancer Detection: The FIND CRC study for colorectal cancer screening is progressing ahead of schedule, with enrollment expected to complete by Q3 2026. This supports an FDA PMA readout in 2027.
Women's Health Growth: The Fetal Focus product is expected to contribute significantly to growth in the women's health business, with an annualized run rate of approximately 200,000 test orders.
MRD Testing Expansion: The company is expanding MRD testing across multiple cancer types and settings, including treatment on molecular recurrence (TOMR) and adjuvant decision-making.
ASP Growth: Signatera ASPs are expected to reach $1,275 by the end of 2026, with further upside potential from private payers and expanded Medicare coverage.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the reason for the conservative gross margin guidance despite a strong quarter?
A:The company is cautious due to potential risk factors to gross margin, such as MRD mix. They did not include all potential drivers in the guidance, leaving room for upside.
Q:Why did SG&A expenses increase as a percentage of sales in Q1?
A:Q1 often has elevated sales and marketing expenses. There were also one-time noncash charges worth about $25 million. Normalizing these gives confidence in the SG&A guide for the rest of the year.
Q:What caused the atypical 92% test recognition rate in Q1 compared to the usual 95%-96%?
A:The high volume of women's health tests in the last two weeks of the quarter led to many units being in process and not reported out yet. This is expected to normalize in subsequent quarters.
Q:What is the latest update on MolDX and its pan-cancer potential?
A:The company has seven additional histologies in submission with MolDX, which could cover the majority of remaining noncovered business. This could add significant value, potentially reaching $2,000 ASP and $750 million in volume and margin.
Q:What are the trends in the women's health segment, particularly with Fetal Focus?
A:Women's health saw strong growth, adding 63,000 units between Q4 2025 and Q1 2026. Fetal Focus orders are not fully counted in this growth, indicating even stronger performance.
Q:What is the status of the LATITUDE product and its reflex testing strategy?
A:LATITUDE is performing well, particularly in CRC. It is used as a reflex when tissue is insufficient, and the company plans to expand it to other tumor types in the future.
Q:What is driving the growth in Signatera tests?
A:Growth is driven by consistent new patient additions, strong repeat rates, and doctors expanding usage within and across histologies. The company is targeting the 50% of oncologists who have not yet used Signatera.
Q:How is the Zenith rare disease product performing?
A:Zenith is in the early stages of launch with low volumes but positive feedback from physicians. The company sees it as a new growth vector.
Q:What is the progress on the CRC launch in Japan?
A:The company expects regulatory approval, reimbursement, and commercial launch within six months. Japan has the same number of CRC diagnoses as the U.S., and the company anticipates significant adoption post-launch.
Q:What are the cost implications for the early cancer detection (ECD) screening asset?
A:R&D costs for the FIND trial are largely reflected in the current guide, with most spending occurring this year and early next year. Commercialization costs will be incremental and based on success, leveraging existing channels.
Q:What is the ramp status of new MRD sales reps?
A:New MRD reps are 50%-75% ramped and are contributing to growth by targeting new customers and cross-selling. The company expects continued momentum from these initiatives.
Q:Did weather impact volumes in Q1?
A:Yes, winter storms in late January caused a step-down in units, but the company still achieved record volumes despite this impact.
Q:What is the adherence rate for Signatera surveillance protocols?
A:Adherence is generally good but varies depending on patient circumstances. There is room for growth as more doctors adopt consistent surveillance protocols.
Q:How does prior authorization impact the business, and what is the outlook?
A:Prior authorization has been a barrier for covered services. Any reduction in prior authorization requirements would be a tailwind for ASPs.
Q:What is the status of the Foresight technology integration into Signatera?
A:The updated Signatera assay with phased variants will launch later this year. It is already available in the research setting and has driven interest, particularly in pharma-sponsored trials.
Q:What is the company's strategy for the CRC launch in Japan?
A:The company plans to secure regulatory approval, reimbursement, and commercial launch within six months. Initial focus will be on the first time point, with plans to expand to surveillance coverage later.
Q:Review of Unclear Management Responses
A:The company avoided providing specific details on the exact adoption ramp for the CRC launch in Japan, stating that they would provide updates as they tighten up the models. Additionally, they did not give a clear timeline for the expansion of LATITUDE to other tumor types, only stating it would happen in the future.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CRC
EV
Fetal Focus
Focus order
Foresight
IMvigor
Japan
TOMR
addition
adoption
arm
bladder cancer
breast cancer
case
change
ctDNA
detection
disease
evidence base
intervention
launch
lymphoma
message
number
oncology
patient MRD
platform
recurrence
scale
setting
surgery
technology
test
therapy
treatment
trial
tumor
type
unit
volume
woman health
NTRA Transcript
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-12
Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call indicates strong growth in MRD tests, positive developments in women's health and oncology segments, and promising progress in international markets like Japan. Although there are concerns about gross margins and SG&A expenses, the company's cautious guidance allows room for upside. The Q&A session reveals optimism in new product launches and partnerships, with potential revenue growth from MolDX submissions. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-12
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Neutral3-5
NTRA Slides
NTRA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
